HealthEquity had its Relative Strength (RS) Rating upgraded from 79 to 88 Friday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
Decades of market research shows that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear a proper buy point.
While revenue growth fell last quarter from 19% to 15%, earnings-per-share grew 21%, up from 10% in the previous report.
The company holds the No. 2 rank among its peers in the Commercial Services-Outsourcing industry group. Red Violet is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
